Introduction {#sec1_1}
============

Organ transplant recipients (OTR) have an increased risk for developing skin cancer, and non-melanoma skin cancers (NMSCs) represent a significant cause of morbidity and mortality in this clinical setting \[[@B1]\]. Actinic keratosis (AK) is considered the precursor lesion of NMSC \[[@B2]\]. In subjects with immune depression, the relative risk of squamous cell carcinoma (SCC) and AKs is substantially higher compared with immunocompetent patients \[[@B3]\]. In OTR subjects, SCC, the most aggressive form of NMSC, is 5 times more frequent than basal cell carcinoma (BCC) and this ratio differs from the general population where BCC is more common than SCC \[[@B1]\]. AK and SCC in OTR subjects commonly involve UV-light-exposed areas \[[@B4]\]. The management of NMSCs in OTRs presents a variety of clinical challenges for physicians \[[@B5]\]. All patients should receive extensive education on UV avoidance and sun protection \[[@B6]\]. The carcinogen-preventive approach is mandatory in areas of field of cancerization and is recommended to reduce morbidity and mortality associated with the progression from AKs to invasive SCC in OTRs \[[@B7]\]. Cyclooxygenase (COX) 1 and 2 enzyme upregulation is involved in the pathogenetic process of AKs and NMSCs \[[@B8]\]. Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) characterized by a non-selective COX-1 and COX-2 inhibition activity \[[@B9]\]. We investigated the effects of a medical device in topical formulation containing piroxicam 0.8% and sunscreen (SPF 50+) (P+SS) on the clearance rates of multiple AKs and field of cancerization in OTR subjects.

Subjects {#sec1_2}
========

We report a 10-case series of OTR patients, 8 men and 2 women, mean age 67 ± 6 years (6 with liver transplantations and 4 with kidney organ transplantations), with histories of extensive AKs. On average, the OT procedure was performed 10 ± 6 years before (range 2--21 years). The main immunosuppressive treatments were tacrolimus in 8 patients and everolimus in 2 subjects. Four subjects were also treated with mycophenolic acid. All these patients were treated with a cream formulation of P+SS, twice daily for 16 weeks. We evaluated, as primary objective, the evolution of AK lesion number, evaluated by clinical mapping of visible lesions, and, as secondary endpoint, the evolution of the Actinic Keratosis Erythema Scale Atrophy (AKESA) score \[[@B10]\] assessing erythema, scale, and atrophy of a target AK lesion. The AKESA score is based on the assessment of the clinical presence of erythema, scale, and atrophy on a target AK lesion. A numeric value from 0 to 3 was attributed to each AK clinical feature (baseline maximum AKESA score: 9) up to complete remission (disappearance of all features in the target lesion, AKESA endpoint score: 0). We also assessed the percentage of treated AKs with complete (100%) or partial (≥75%) clearance and evaluated skin tolerability with this medical device. Finally, we also evaluated at baseline and after 16 weeks the following dermoscopic features of the target lesion: erythematous pseudo-network (strawberry pattern) on the facial lesions, erythematous background on the other sites, whitish-yellowish surface scales, and atrophic hypopigmented areas, according to Zalaudek et al. \[[@B11]\].

Results {#sec1_3}
=======

At baseline, the total lesion count was 51 (44 lesions Grade 1--2 and 7 lesions Grade 3) with an average lesion number of 5.1 per patient. Adherence to treatment was evaluated by counting the empty tubes returned at each visit. Three out of 10 patients showed complete clinical clearance after 16 weeks of treatment with P+SS. Four additional patients showed a marked (≥75% lesion count reduction) improvement in their overall AK lesion count in the treatment area. A relevant improvement was also observed under dermoscopic observation of the target lesions (Fig. [1](#F1){ref-type="fig"}). Two patients showed a 30% lesion count reduction in the treated area. The overall AK lesion count decreased from 51 at baseline to 13 at the end of treatment, representing a 75% reduction in lesion count. Grade 1 and 2 lesions respond better than Grade 3 type lesions. In these lesions, the AKESA score was also markedly reduced after treatment: the total AKESA score was 81 and 23 (−72%) before and after P+SS, respectively. A clinical improvement of field cancerization in 1 subject is shown in Figure [2](#F2){ref-type="fig"}. Adverse events were limited to mild local irritation. No systemic side effects were reported. The good local tolerability was in line with clinical data published \[[@B26], [@B27]\].

Discussion {#sec1_4}
==========

Immunosuppressive treatment in OTR is mandatory to maintain an adequate graft function \[[@B12]\]. However, immunosuppression carries an increased risk for the development of cancers, especially epithelial skin cancer \[[@B13]\]. Skin cancers are a major part of OT-related morbidity and mortality \[[@B14]\]. In OTR subjects, BCC and SCC account for more than 90% of skin cancer manifestations \[[@B15]\]. We reported here the efficacy of a medical device containing P+SS in a case series of 10 OTRs. Piroxicam is an enolic benzothiazine and a member of the oxicam series, structurally different from diclofenac \[[@B16]\]. In contrast with diclofenac, piroxicam is characterized by a potent COX-1 inhibitory action \[[@B17]\]. The agent suppresses the synthesis of pro-inflammatory enzymes such as prostaglandins (mainly PgE) and tromboxanes \[[@B18]\]. Piroxicam inhibits polyamine production by blocking ornithine decarboxylase induction \[[@B19]\]; these pathways are involved in skin carcinogenesis \[[@B20]\]. In contrast to diclofenac, piroxicam is also able to induce apoptosis and suppress metalloproteinase 2 and 9 activities \[[@B21], [@B22]\], the most prominent proteinase family associated with tumorigenesis \[[@B23]\]. Recently, a medical device containing P+SS has been evaluated in AK subjects. Prospective clinical trials have shown that sun filters in AK subjects prevent the appearance of new AK lesions \[[@B24]\], therefore combining a cyclooxygenase inhibitor and sunscreen filters in a single product could have a strong rationale. In the trials evaluating the efficacy of diclofenac in AK, subjects were advised to concomitantly also use sunscreens and to avoid excessive exposure to the sun \[[@B25]\]. This two-component medical device could therefore have the advantage of improving subject adherence to the therapy. The clinical efficacy of P+SS in the treatment of AK was evaluated in two controlled multicenter trials \[[@B26], [@B27]\] involving a total of 108 subjects. The treatment of P+SS in this clinical setting induced a reduction in AK lesions of more than 55%. This medical device was also very effective in an immune-depressed subject with a history of Kaposi sarcoma and multiple AK lesions unresponsive to previous ablative treatments \[[@B28]\]. Piroxicam, in contrast with diclofenac, expresses antioxidant \[[@B29]\] and antiviral \[[@B30]\] actions. The latter could be of relevant interest because infection of human papillomaviruses is associated with an increased risk of NMSC \[[@B31]\]. In renal transplant subjects, Berkhout et al. \[[@B32]\] showed that human papillomavirus tends to persist in premalignant skin lesions. However, the anti-viral action of piroxicam from a clinical point of view should at the moment be considered speculative regarding this clinical setting.

Conclusions {#sec1_5}
===========

The use of piroxicam and sunscreen in OTRs is safe due to the lack of local and systemic immunogenic effect, which is not recommended in this class of patients. Moreover, the usefulness of this new formulation combining the anticancer effect of piroxicam with the chemopreventive action of sunscreens could be considered a new long-term therapeutic strategy, which is mandatory in these OTRs. Prospective studies are needed to investigate the efficacy and safety of this therapy in greater numbers of these patients.
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